Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

"It is extremely gratifying to have gone though the first laboratory determinations, to clinical trials, and to see Herceptin impact on increasing survival. That is a hard endpoint to obtain, and it ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...